James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 10,810 shares at $32.27 ($350K) on 2026-09-10, disclosed to the SEC on 2026-09-14.
Open-market sale of $350k AMLX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.27 | 9,768 | $315K | 90.1% |
| 2 | $33.23 | 1,042 | $35K | 9.9% |
| Total | $32.36 avg | 10,810 | $350K | 100% |
| Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |
| AMLX | SELL | 2025-04-02 | $38K | — | Filing → |